739 related articles for article (PubMed ID: 26069190)
1. ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.
Shen J; Peng Y; Wei L; Zhang W; Yang L; Lan L; Kapoor P; Ju Z; Mo Q; Shih IeM; Uray IP; Wu X; Brown PH; Shen X; Mills GB; Peng G
Cancer Discov; 2015 Jul; 5(7):752-67. PubMed ID: 26069190
[TBL] [Abstract][Full Text] [Related]
2. Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy.
Park Y; Chui MH; Suryo Rahmanto Y; Yu ZC; Shamanna RA; Bellani MA; Gaillard S; Ayhan A; Viswanathan A; Seidman MM; Franco S; Leung AKL; Bohr VA; Shih IM; Wang TL
Clin Cancer Res; 2019 Sep; 25(18):5584-5594. PubMed ID: 31196855
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors.
Yu ZC; Li T; Tully E; Huang P; Chen CN; Oberdoerffer P; Gaillard S; Shih IM; Wang TL
Cancer Res; 2023 Aug; 83(16):2750-2762. PubMed ID: 37306706
[TBL] [Abstract][Full Text] [Related]
4. PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer.
Chabanon RM; Morel D; Eychenne T; Colmet-Daage L; Bajrami I; Dorvault N; Garrido M; Meisenberg C; Lamb A; Ngo C; Hopkins SR; Roumeliotis TI; Jouny S; Hénon C; Kawai-Kawachi A; Astier C; Konde A; Del Nery E; Massard C; Pettitt SJ; Margueron R; Choudhary JS; Almouzni G; Soria JC; Deutsch E; Downs JA; Lord CJ; Postel-Vinay S
Cancer Res; 2021 Jun; 81(11):2888-2902. PubMed ID: 33888468
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency.
Yang L; Yang G; Ding Y; Huang Y; Liu S; Zhou L; Wei W; Wang J; Hu G
Oncol Rep; 2018 Jul; 40(1):479-487. PubMed ID: 29767248
[TBL] [Abstract][Full Text] [Related]
6. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response.
Mandal J; Mandal P; Wang TL; Shih IM
J Biomed Sci; 2022 Sep; 29(1):71. PubMed ID: 36123603
[TBL] [Abstract][
